76
Registered trials
36
Recruiting
35
Completed trials
53
Sponsors
26
Countries
Phase III:
32
Phase II/III:
5
Phase II:
23
Phase I/II:
12
Phase IV:
1
Phase I (Other):
2
Phase I (FiH):
1
Oversight events:
7 serious breaches
31 temporary halts
4 urgent safety measures
3 corrective measures
across 10 trials
View oversight register →
Indications tested
Acute myeloid leukaemia
6
Diffuse large B-cell lymphoma
4
High-grade B-cell lymphoma
3
Primary mediastinal large B-cell lymphoma
2
Mantle cell lymphoma refractory
2
Myelodysplastic syndrome
2
Diffuse large B-cell lymphoma stage III
1
Mantle cell lymphoma
1
Mantle cell lymphoma stage III
1
Acute lymphocytic leukaemia
1
B-cell small lymphocytic lymphoma
1
Chronic lymphocytic leukaemia
1
Sponsors using this IMP
Fondazione Gimema Franco Mandelli Onlus
8
Novartis Pharma AG
4
Karolinska University Hospital
3
Prinses Maxima Centrum voor Kinderoncologie B.V.
3
Technische Universitat Dresden
3
Amgen Inc.
2
Fondazione Italiana Linfomi Ets
2
Medical University Of Lodz
2
Moleculin Biotech Inc.
2
The University Of Birmingham
2
Universitaetsklinikum Muenster AöR
2
Universitaetsklinikum Ulm AöR
2
All trials — page 4
76 totalShowing 73–76 of 76 trials